novascit is another id for the same moron that uses the nuke, betsy, boley ids, along with about 1,000 others. At one time this fool worked as a bed pan cleaner at the medical center in Houston, Texas. Someone on another board had gone to the trouble and expense to track him down, or at least that's what was said.
whatever nukedummy, stock is undervalued, but keep on bashing, you're comical but in a stupid sort of way. Finish off the rot gut and come back as your nuke id. Was it a rough day with the bed pans again?
novasometool is another nukie id along with betsy, fetid, boley, mzr, and hundreds of others. nukie id won't be used until he finishes off his first bottle of rot gut. Trailer park hedge fund guru, what a life. lmao.
Plenty of non-dilutive money floating around out there, just like the $200,000,000.00 nvax recently received from big brother. Company at the point where more large donations are coming our way. To be expected that a dumbscit who continues to preach about dilutions can't appreciate the importance of non-dilutive funding that's readily available to nvax.
Interest in novasome to disappear from these board, these rise classic bashing pattern, like you can see now, post pattern seem lie, recheck $2.77 later on!
novasome, you're worst than norse ever thought about being, reply to everything with your BS. Another basher dummy is all you are. New Big competition on the scene, you're full of scit. Novartis is many trials and years behind nvax. RSV results soon, and many phase III trials next, nvax is the game changer. I expect another incoherent response from you.
nukeadummy, you originally said that no phase II studies were completed. Not true, phase II studies have been completed. Will there be more studies prior to going into phase III, yes possibly, but that's not what your original statement said. If you were providing honest information instead of lying to bash the stock, there wouldn't be an interpretation difference. What about that buy recommendation at $2.32 just the other day, let me guess, you decided not to buy right, what a bed pan cleaning tool.
Not to mention all your worthless ids, nukeasuc. I told you where to go to verify the completed phase II studies, but obviously you can't figure it out. All of your posts are total lying scit.
nukeadumbacc, no answer I see, if it ain't a picture you can't comprehend it. Go to clinical trials under clinical pipeline, all studies I listed are marked as complete.
Go to the nvax web site, click on clinical pipeline, then select clinical trials. Then click on the actual trials and check for the "STUDY COMPLETED" notation on the left top of the study. It's reported as complete on the website on the actual study, but I understand why you prefer pictures. You said no phase II studies were complete, according to the website that's in error, and yes I'm sure it does suc to be pearson.
I posted a response to your dumbacc yesterday. All phase II completed below. More free money on the way, non-dilutive all the way to product launch. A simpleton like yourself needs to understand when you get free money to the tune of $200 million or more you have to work things through with consideration for your donors. Lots of studies are headed to phase III very soon. You been buying and selling vapor shares lately? What a dumbphuk.
Novavax NCT01561768: A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults - Study Completed!
Novavax NCT01014806: Phase IIa trial to evaluate the safety and immunogenicity of a trivalent seasonal influenza virus-like-particle (VLP) vaccine (recombinant) in older adults - Study Completed!
Novavax NCT01072799: Phase II trial to assess the safety and immunogenicity of an A (H1N1) 2009 Influenza virus-like particle (VLP) Vaccine - Study Completed!
Novavax NCT00903552: Phase IIa randomized, double blind, placebo controlled trial to evaluate the safety and immunogenicity of a trivalent seasonal influenza virus-like particle (VLP) vaccine (recombinant) in healthy adults - Study Completed!
Novavax NCT00519389: Phase I/IIa Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of an H5N1 Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) - Study Completed!
Novavax NCT00754455: A Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults - Study Completed Less